Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
AAPS Pharmscitech|April 23, 2026
Liposome-Based Drug Delivery Systems: Mechanisms, Preparation Strategies, Clinical Status, and Therapeutic ApplicationsAbdul Shadab, Md Faheem Haider, Mohammad Abohassan
Journal of Biomolecular Structure & Dynamics|July 23, 2022
Identification of second generation benzylidene chromanone analogues as novel, potent DHODH inhibitors in acute myeloid leukemia cellsMohammad Abohassan, Mesfer Al Shahrani, Prasanna Rajagopalan
Molecular Biology Reports|June 30, 2026
Ethosomal nanocarriers for enhanced skin drug delivery: a comprehensive reviewDaniyal Khan, Md Faheem Haider, Mohammad Abohassan
Naunyn-Schmiedeberg'S Archives of Pharmacology|July 27, 2026
Lipid-based nanocarrier-enabled combination therapy for breast cancer: overcoming drug resistance toward precision oncologyAbdul Shadab, Md Faheem Haider, Mohammad Abohassan
Medical Oncology (Northwood, London, England)|October 8, 2022
Insilco and Invitro approaches identify novel dual PI3K/AKT pathway inhibitors to control acute myeloid leukemia cell proliferationsMohammad Abohassan, Mesfer Alshahrani, Mohammad Y Alshahrani, et al.
Saudi Journal of Biological Sciences|May 20, 2022
CB-RAF600E-1 exerts efficacy in vemurafenib-resistant and non-resistant-melanoma cells via dual inhibition of RAS/RAF/MEK/ERK and PI3K/Akt signaling pathwaysMesfer Al Shahrani, Prasanna Rajagopalan, Mohammad Abohassan, et al.
Medical Oncology (Northwood, London, England)|October 16, 2025
Selectively targeting the IKKβ by 11,11'-methylenebisdibenzo[a, c]phenazine (SIKB-7543) downregulates aberrant NF-κB signaling to control the proliferation and induce apoptosis in Hodgkin lymphomaMohammad Abohassan, Mesfer Mohammad Al Shahrani, Sarah Khaled AlOuda, et al.
Oncology Research|March 20, 2025
Dibenzo [a, c] phenazin-11-yl(phenyl) methanone (SBLJ23), a novel selective inhibitor targeting JAK2V617F mutation in myeloproliferative neoplasmsMohammad Abohassan, Mesfer Mohammad Al Shahrani, Sarah Khaled Alouda, et al.
Medical Oncology (Northwood, London, England)|March 13, 2025
Dual targeting of CXC chemokine receptor 4 and multidrug resistance protein 1 by ZIN056 effectively combat daunorubicin resistance in acute myeloid leukemia cellsMohammad Abohassan, Mesfer Mohammad Al Shahrani, Sarah Khaled AlOuda, et al.
Biochemical and Biophysical Research Communications|January 6, 2025
Identification of 8-(2-methyl phenyl)-9H-benzo[f]indeno[2,1-c]quinolin-9-one (C-5635020) as a novel and selective TGFβ RII kinase inhibitor for breast cancer therapyMesfer Al Shahrani, Mohammad Abohassan, Mohammad Alshahrani, et al.
Pageof 5